ACTEMRA reduces symptoms, symptoms in patients with rheumatoid arthritis Genentech, Inc. Additionally, combined data from three additional Phase III studies showed that RA patients who received ACTEMRA got sustained improvements in signs or symptoms over nearly two years. These data will end up being presented at the 2010 American College of Rheumatology Annual Scientific Interacting with in Atlanta, November 7-11, 2010. Data presented at ACR provide additional evidence of the long-term benefits of Actemra in reducing the signs and symptoms in individuals with moderate to severe RA, stated Hal Barron, M.D., executive vice president, Product Development and chief medical officer.Four patients who offered relapses of multiple sclerosis were treated intermittently with corticosteroids. A complete of 19 magnetic resonance imaging studies were performed through the research period in 11 sufferers . These studies were performed routinely at 12 months in six patients and in five individuals when fresh neurologic symptoms arose that differed from these individuals’ normal flares of multiple sclerosis. Non-e of the MRI scans demonstrated brand-new lesions suggestive of PML. Natalizumab was withdrawn after 12 months in Sufferers 1, 14, 16, and 17 to determine a drug holiday, following a report of new natalizumab-associated cases of PML,5 and these four patients weren’t studied further at 18 months.